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The pleiotropic activities of Interleukin (IL-)6 are controlled by membrane-bound and soluble forms of the 22 IL-6 receptor (IL-6R) in processes called classic and trans-signaling, respectively. The coding single nucleo-23 tide polymorphism (SNP) rs2228145 of the Interleukin 6 receptor (IL-6R Asp358Ala variant) is associated 24 with a 2-fold increase in soluble IL-6R (sIL-6R) serum levels resulting in reduced IL-6-induced C-reactive 25 protein (CRP) production and a reduced risk for coronary heart disease. It was suggested that the increased 26 sIL-6R level leads to decreased IL-6 classic or increased IL-6 trans-signaling. Irrespective of the functional 27 outcome of increased sIL-6R serum level, it is still under debate, whether the increased sIL-6R serum levels 28 emerged from differential splicing or ectodomain shedding. Here we show that increased proteolytic 29 ectodomain shedding mediated by the A Disintegrin and metalloproteinase domain (ADAM) proteases 30 ADAM10 and ADAM17 caused increased sIL-6R serum level in vitro as well as in healthy volunteers homo-31 zygous for the IL-6R Asp358Ala allele. Differential splicing of the IL-6R appears to have only a minor effect on 32 sIL-6R level. Increased ectodomain shedding resulted in reduced cell-surface expression of the IL-6R Asp358Ala 33 variant compared to the common IL-6R variant. In conclusion, increased IL-6R ectodomain shedding is a mech-34 anistic explanation for the increased serum IL-6R levels found in persons homozygous for the rs2228145 IL-6R 35 Asp358Ala variant. 36 © 2014 Published by Elsevier B.V.
leads to an amino acid substitution of aspartic acid to alanine (Ala)
75
at amino-acid position 358 within the extracellular domain of the IL-6R
76
(Asp358Ala) and is strongly associated with a two-fold increase in sIL-6R 77 levels [10, 11] . In Europe, the Asp358Ala mutation is rather common, as it 78 has a minor allele frequency (MAF) of 30-40% [12] . This SNP was recently x-fold increase in sIL-6R Fig. 1 . The coding single nucleotide polymorphism (SNP) rs2228145 (Asp358Ala) is associated with increased soluble IL-6R levels in humans. A. Schematic representation of the human IL-6R consisting of an Ig-like domain (D1), the two domains containing the cytokine-binding module (CBM, D2 and D3), the stalk region, transmembrane and intracellular domain. The ADAM17 cleavage site between Gln357 and Asp358 is indicated with a black triangle. B. Chromatograms showing the SNP rs2228145 (Asp358Ala) in exon 9 of IL6R. Upper panel shows a wildtype situation (358Asp, A/A), whereas the lower panel shows a human homozygous for the mutation (358Ala, C/C). C. Full blood was taken from five healthy donors homozygous for the IL-6R SNP rs2228145 (referred to as C/C) and five healthy donors not carrying the SNP as controls (referred to as A/A) by venipuncture and serum isolated. Determination of sIL-6R levels within the serum was performed with an ELISA specific for hIL-6R. D. Serum levels of sgp130 were determined in the serum samples described under C with an ELISA specific for sgp130. E. Serum levels of IL-6 were determined in the serum samples described under C with an ELISA specific for human IL-6. F. PBMCs were isolated pair-wise from fresh blood of humans with the A/A or C/C IL-6R genotype (see Materials and methods for details). Equal amounts of PBMCs were incubated for 2 h, and the amount of sIL-6R in the supernatant of the PBMCs was quantified with an ELISA specific for the IL-6R. The data shown in this graph are the mean ± S.D. of five independent experiments. G. The serum samples of the 10 healthy donors described under panel C were analyzed with an ELISA that specifically recognizes only the differentially spliced hIL-6R, but not the sIL-6R generated by limited proteolysis. Samples below the detection limit (b31.25 pg/ml) are shown with a symbol directly on the x-axis. In graphs B, C, D and F, each symbol represents the mean of the ELISA measurement for the individual participants. The horizontal lines indicate the mean of each group. P-values of the statistical analysis are given above the respective figure.
signaling in target cells due to lower membrane-bound IL-6R expres- ionomycin were purchased from Sigma-Aldrich (Steinheim, Germany).
106
The anti-hIL-6R mAb tocilizumab (RoACTEMRA) was kindly provided
107
by Roche (Grenzach, Germany) and GI254023X and GW280264X by
108
Glaxo Smith Kline (Stevenage, UK) [26] . pcDNA3.1 containing human IL-6R was previously described [7] .
111
The point mutation hIL-6R-Asp358Ala was introduced using standard from at least three independent experiments unless otherwise stated.
184
Statistical analysis was performed using a one-tailed Mann-Whitney-
185
U test. P-values are either given directly within the figures, or a P-value 186 below 0.05 is indicated with an asterisk (*). 
juxtamembrane stalk region of the IL-6R has been determined to be lo- n. s. hIL-6R
hIL-6R Asp358Ala
shIL-6R [% compared Fig. 3 . Constitutive and stimulated shedding of the interleukin 6-receptor variant Asp358Ala is increased compared to the common IL-6R variant. A. HEK293 cells were transiently transfected with expression plasmids coding for IL-6R wildtype and Asp358Ala. Cells were equally distributed one day later onto 6 well-plates, and stimulated 24 h later for 60 min with 1 μM ionomycin (Iono) or treated with DMSO as negative control. The soluble IL-6R in the supernatant was quantified via ELISA. The amount of soluble wildtype IL-6R was set to 100%, and all other values were calculated accordingly. ELISA results show the mean ± S.D. of three independent experiments. B. The experiment was performed as described under panel A, except that cells were stimulated with 100 nM PMA for 120 min. C. HEK293 cells were transiently transfected with expression plasmids coding for IL-6R wildtype and Asp358Ala. Cells were equally distributed one day later onto 6 well-plates. The next day, medium was replaced and conditioned media collected at the time points indicated. The soluble IL-6R in the supernatant was quantified via ELISA. C. The experiment described under panel C was performed with NIH3T3 cells. E. The experiment was performed as described under panel A. Cells were pretreated for 30 min with the metalloprotease inhibitors GI (specific for ADAM10) or GW (specific for ADAM10 and ADAM17) where indicated. One representative experiment of three performed is shown. F. The experiment was performed as described under panel C, except that cells were stimulated with 100 nM PMA for 120 min. One representative experiment is shown.
0.004; Fig. 1C) . Importantly, the rs2228145 SNP solely influenced 215 sIL-6R serum levels, since neither sgp130 (A/A: 170.9 ± 24.5 ng/ml; 216 C/C: 165.9 ± 21.9 ng/ml: p = 0.5; Fig. 1D ) nor IL-6 (A/A: 17.8 ± 217 14.8 pg/ml; C/C: 19.2 ± 31.9 pg/ml; p = 0.21; Fig. 1E ) showed any 218 statistical significant difference between the two groups investigated. tive C-terminus of DS-sIL-6R but not the proteolytically processed sIL-
237
6R revealed that below 1% of the sIL-6R is generated by differential splic-238 ing (Fig. 1G) , which is consistent with other studies [32, 33] . We can, MEFs were transiently transfected with expression plasmids coding for IL-6R wildtype and Asp358Ala. The level of IL-6R expression was determined by Western blotting, and β-actin served as internal loading control. B.-E. The indicated MEFs were stimulated for 60 min with 1 μM ionomycin (Iono) or 2 h with 100 nM PMA. DMSO was used as negative control for each stimulation (either 1 h or 2 h). Afterwards, sIL-6R in the cell supernatants was quantified via ELISA. In each panel, one out of three experiments with similar outcome is shown.
contributes to the overall generation of the sIL-6R found in human 251 plasma. lower compared to the common IL-6R variant ( Fig. 2A) , even though 261 cellular IL-6R expression was comparable (Fig. 2B) . Both IL-6R variants
262
were able to induce IL-6 dependent signaling in stable transduced
263
Ba/F3-gp130 cells, which could be blocked by the monoclonal antibody 264 tocilizumab (Fig. 2C) . Using confocal microscopy, intense cell surface 265 staining for the common IL-6R variant was detected (Fig. 2D, top   266 panel), whereas the IL-6R Asp358Ala variant was only sparely detected 267 on the cell surface (Fig. 2D, lower panel) . Taken 
306
We set the amount of sIL-6R after stimulation to 100% and calculated IL-6R shedding [%] x-fold increase in sIL-6R In all experiments, equal amounts of PBMCs were used, and the amount of sIL-6R in the supernatant of the PBMCs quantified with an ELISA specific for the IL-6R. Cells were stimulated as follows: A. 1 μM ionomycin (1 h), B. 100 nM PMA (2 h), C. 1 μM ionomycin plus either 3 μM GI or GW, D. 100 nM PMA plus either 3 μM GI or GW. Cells were pre-incubated with the inhibitors 30 min before addition of either PMA or ionomycin. P-values of the statistical analysis are given above the respective figure.
was blocked by GI and GW or only GW, respectively (Fig. 3E and F) . (Fig. 4A) . If the increased shedding of the IL-6R Asp358Ala IL-6R variant 337 would be due to an increased protein biosynthesis than increased IL-6R 338 expression of the Asp358Ala IL-6R variant would have been expected.
339
Again constitutive and ionomycin-or PMA-induced shedding of the 340 Asp358Ala IL-6R variant was slightly increased compared to the com-341 mon IL-6R variant (Fig. 4B) . ADAM10 deficient MEFs also released 342 more sIL-6R after ionomycin-and PMA-stimulation (Fig. 4C) . Although increased compared to common IL-6R variant, respectively (Fig. 5A, B) .
372
Ionomycin and PMA-induced shedding was significantly suppressed 373 by co-incubation with GI and GW or GW alone, respectively
374
( Fig. 5C, D) , indicating that the sIL-6R was generated by ADAM10- tive shedding under non-PKCα-overexpressing conditions.
394
We verified these findings via flow cytometry. Whereas we ob-395 served only a very small reduction of cell-surface IL-6R when we stimu-396 lated HEK293 cells transfected with wildtype IL-6R (Fig. 6B) , the cell-397 surface reduction of the Asp358Ala variant was more pronounced 398 after PMA stimulation (Fig. 6C) , thus reflecting the ELISA measurements 399 (Fig. 6A) . Interestingly, the majority of the IL-6R appeared to be still an increased cell-surface loss of both IL-6R variants ( Fig. 6D and E However, our data show that ADAM17 might favor the cleavage after 443 a small, non-charged amino acid like alanine instead of aspartic acid.
444
IL-6 is found in the blood at 1-5 pg/ml but increases to ng/ml con- CRP level [8, 9] . Two different mechanisms might be responsible for 450 this, or may act in concert. Circulating IL-6 will bind to sIL-6R and subse-451 quently to sgp130, which is the natural inhibitor of the IL-6 trans- 
